Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols

Protocols

EDRN investigators protocols. The following is a list of the EDRN protocols that have been captured and curated. Additional information will be added as it is available. Contact information is provided as part of the detail for each protocol.

Contents

Title Abstract Investigator
Biomarkers and clinical parameters associated with Gleason score upgrading Thompson, Ian M.
Biomarkers for Prostate and Bladder Cancer CD26+ cancer cells and CD90+ tumor-associated stromal cells were sorted from tumor tissue. Dataset analysis with transcriptomes of CD26+ luminal, CD104+ basal, ... Liu, Alvin Y.
Biomarkers for early detection of pancreatic cancer Background: The clinical management of pancreatic cancer is severely hampered by the absence of effective screening tools. Methods: Sixty-seven biomarkers ... Lokshin, Anna
Biomarkers for the Early Detection of Pancreatic Cancer Killary, Ann M.
Biomarkers in Familial Multiple Myeloma Lynch, Henry
Biomarkers of Risk for Colorectal Neoplasia To explore biomarkers of risk of adenoma and adenoma recurrence Schoen, Robert E.
Biomarkers of Risk for Colorectal Neoplasia (Team Project #2) Investigators in the colon section of EDRN have a mutual interest in developing markers that would identify individuals at increased risk for colon neoplasia. ... Schoen, Robert E.
Biomarkers to Distinguish Aggressive Cancers from Non-aggressive or Non- progressing cancers We hypothesize that our novel Biomarker Panel of Auto-antibodies can distinguish aggressive, symptom diagnosed lung cancer from non-aggressive, screen-detected ... Rom, William
Biomarkers to Distinguish Aggressive Cancers from Non-aggressive or Non-progressing Cancer Distinguishing aggressive cancers from non-aggressive or non-progressing cancers is an issue of both clinical and public health importance particularly for ... Li, Christopher
Body Fluids as a Source of Diagnostic Biomarkers Semmes, John
Body Fluids as a Source of Diagnostic Biomarkers: Breast Semmes, John
Body Fluids as a Source of Diagnostic Biomarkers: Prostate Recent advances in high-throughput protein expression profiling of bodily fluids has generated great enthusiasm and hope for this approach as a potent ... Semmes, John
Breast Cancer: subgroups specific blood-biomarkers for early / predictive diagnosis and personalized treatment Breast-conserving lumpectomy followed by radiation therapy has been shown to be an alternative strategy, competitive to mastectomy, in preventing mortality ... Golubnitschaja, Prof. Dr. Olga
Breast Ductal Lavage Fluid Specimen Bank Trock, Bruce
Breast Ref Applicant: Abbott Arkansas Medical Sciences 2013 Abbott, Karen
Breast Ref Applicant: Chris Li (2014) Li, Christopher
Breast Ref Applicant: Mukherjee 2014 Mukherhjee, Pinku
Breast Ref Set Applicant: Anu Mathew-Meso Scale 2012 Mathew, Anu
Breast Reference Set Applicant-Tuszynski-Temple (2012) Feng, Ziding
Breast Reference Set Applicant:- Zangar-Pacific NW Nat'l Laboratory (2012) Feng, Ziding
Breast tissue array Chia, David
CLUE Studies: Evaluating Biomarkers of Carcinogenesis Helzlsouer, Kathy
Canary TMA This protocol describes a multi-center, retrospective, case-cohort tissue microarray (TMA) study to evaluate tissue biomarkers for their ability to predict ... Nelson, Peter S
Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients BACKGROUND: Carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC-Ag), and CYFRA 21-1 are the most useful markers for non-small cell lung ... Kulpa, Jan
Chemokine Prostate Cancer Biomarkers STUDY DESIGN 1. The need for pre-validation studies. Preliminary data from our laboratory demonstrates a potential utility for CXCL5 and CXCL12 as biomarkers ... Macoska, Jill
Clinical Proteomic Technologies for Cancer Initiative (CPTAC) Phase I CPTAC Phase I 2006 - 2011, was developed to address the pre-analytical and analytical variability issues that are major barriers to the field of proteomics. ... Kinsinger, Chris
Clinical Proteomic Technologies for Cancer Initiative (CPTAC) Phase II The objective of the "System Suitability (CompRef) Study" was to validate mass spectrometry protocols used at each Proteome Characterization Center (PCC). Kinsinger, Chris
Clinical Utility of Urinary CD90 as a Biomarker for Prostate Cancer Detection Tumor-associated stromal cells differ from normal gland-associated stromal cells in gene expression. Genes up-regulated in these stromal cells are potential ... Liu, Alvin Y.
Clinical Validation of Molecular Signatures of Cervical Neoplasia Unger, Elizabeth R.
Clinical and Analytical Validation of Cancer Biomarkers: Developmental Studies Chan, Daniel
Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.
Announcement 09/14/2014

Thank you to everyone who helped make the 9th EDRN Scientific Workshop a success. We look forward to seeing everyone at the 28th EDRN Steering Committee Meeting from March 31-April 2, 2015, in Atlanta, GA.